YPrime Honored as Trailblazer in Clinical Trial Patient Engagement

YPrime

MALVERN, PA — YPrime has been recognized as a Trailblazer in the Everest Group’s Clinical Trial Patient Engagement Products Assessment. This accolade highlights YPrime’s dedication to enhancing patient participation and engagement in clinical trials with cutting-edge, experience-focused technology.

“We are thrilled to be named a Trailblazer by the Everest Group,” stated Jim Corrigan, CEO of YPrime. “This recognition shows that our hard work in transforming clinical trials is paying off. At YPrime, we have always considered ourselves trailblazers, constantly pushing the boundaries of what is possible in patient engagement and clinical trial technologies for all stakeholders in the ecosystem.”

Patient engagement is increasingly crucial to the success of clinical trials, serving as a key factor for trial retention, data accuracy, and regulatory compliance. The adoption of digital technology is becoming essential in clinical trials, with patient-centric approaches becoming foundational to better trial outcomes.

YPrime’s patient engagement solutions, notably their eConsent and eCOA platforms, use user-friendly designs, personalization, and behavioral science to improve patient retention and adherence. “Our technology isn’t just built on user-centric design principles – it’s driven by them,” explained Mike Hughes, Chief Product Officer at YPrime. “We’ve got a dedicated team that is focused on patient needs, including researchers who work directly with trial participants. This approach does not just enhance the patient experience; it revolutionizes trial efficiency and site productivity.”

Recent innovations from YPrime include the launch of eCOA 7.0, a no-code, configurable platform that accelerates study launches by 30%, supporting both complex and simple trials. The platform provides benefits for patients, sites, and sponsors with faster startup, high-quality data, and operational efficiencies. Additionally, YPrime has introduced patient-centric features like glucometer integration and the Tender Swollen Joint Count assessment, developed to enhance data quality and compliance.

READ:  Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil

YPrime’s recognition as a Trailblazer reflects its efforts to pioneer patient-centric technologies that advance clinical trials and improve outcomes for all participants in the clinical trial ecosystem.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.